Cannabidiol in inflammatory bowel diseases: A brief overview

 

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis

 

Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and

other treatment-resistant conditions?

 

Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation

 

Therapeutic potential of cannabinoid-based drugs

 

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)

 

Cannabinoids and the gut: New developments and emerging concepts

 

Endocannabinoids and the gastrointestinal tract

 

Cannabinoids and gastrointestinal motility: Animal and human studies